Mustang Bio (MBIO) Competitors

Lexaria Bioscience currently has a consensus price target of $1.50, indicating a potential upside of 116.45%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Lexaria Bioscience is more favorable than Mustang Bio.

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lexaria Bioscience has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Mustang Bio has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,685.84%. Mustang Bio's return on equity of -29.78% beat Lexaria Bioscience's return on equity.

Mustang Bio has lower revenue, but higher earnings than Lexaria Bioscience. Mustang Bio is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

In the previous week, Mustang Bio had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 1 mentions for Mustang Bio and 0 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Allarity Therapeutics presently has a consensus target price of $9.75, suggesting a potential upside of 596.43%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Allarity Therapeutics is more favorable than Mustang Bio.

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 0.0% of Allarity Therapeutics shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Allarity Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Mustang Bio's return on equity of -29.78% beat Allarity Therapeutics' return on equity.

Mustang Bio has lower revenue, but higher earnings than Allarity Therapeutics. Mustang Bio is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Allarity Therapeutics had 2 more articles in the media than Mustang Bio. MarketBeat recorded 3 mentions for Allarity Therapeutics and 1 mentions for Mustang Bio. Allarity Therapeutics' average media sentiment score of 0.49 beat Mustang Bio's score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Mustang Bio has lower revenue, but higher earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Mustang Bio's return on equity of -29.78% beat Exicure's return on equity.

42.8% of Exicure shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Mustang Bio had 1 more articles in the media than Exicure. MarketBeat recorded 1 mentions for Mustang Bio and 0 mentions for Exicure. Exicure's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Exicure has a beta of 3.62, indicating that its share price is 262% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Mustang Bio has higher earnings, but lower revenue than VYNE Therapeutics. Mustang Bio is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Mustang Bio has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,646.14%. Mustang Bio's return on equity of -29.78% beat VYNE Therapeutics' return on equity.

In the previous week, Mustang Bio had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 1 mentions for Mustang Bio and 0 mentions for VYNE Therapeutics. Mustang Bio's average media sentiment score of 0.00 equaled VYNE Therapeutics'average media sentiment score.

Mustang Bio has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.

10.0% of Mustang Bio shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 4.0% of Mustang Bio shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.